At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 336 enrolled
Drug / intervention
Indocyanine Green (ICG) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot/Feasibility Study of Intraoperative Image-Guided Surgery of CNS Tumors With Indocyanine Green and MR Spectroscopic Imaging
In Brief
A Phase 2 clinical trial evaluating Indocyanine Green (ICG) and Intraoperative near-infrared (NIR) for Suspected Central Nervous System Tumors. Completed, enrolled 336 participants across 1 site.
Detailed Summary
This study is a single center, open-label, two-part study to assess image guided surgery of intramolecular imaging in nervous system tumors. Subjects with a diagnosis of a resectable nervous system tumor who are at risk of recurrence are included. The primary goal is to observe what tissues fluoresce in the OR, and then to identify if that tissue is cancerous/tumor or normal when the histopathology is performed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSuspected Central Nervous System Tumors
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedMar 2016
Primary CompletionFeb 2020
Study CompletionApr 2020
TodayJul 2026
First PostedMar 16, 2016
Enrollment StartJun 10, 2015
Primary CompletionFeb 4, 2020
Study CompletionApr 2, 2020
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 10.3 years ago
Interventions
Indocyanine Green (ICG)drug
Intraoperative near-infrared (NIR)radiation